AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV

FDA approval of the glecaprevir/pibrentasvir combination could help AbbVie fill a gap resulting from declining sales of Viekira Pak, while challenging Gilead's monopoly in some segments of the market.